GlassScriptPhysician profile
Erin K Yu
NPI 1225028087
$4,663.79
in general payments reported to CMS, 2019-2025
38 companies · $530 in 2025
The $530 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $358 · 2021: $630 · 2022: $1,241 · 2023: $722 · 2024: $725 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.48 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $777.54 | 2019-2025 | Lo Loestrin Fe, Ubrelvy, Liletta |
| Astellas Pharma US INC | $550.65 | 2022-2025 | Veozah, Myrbetriq |
| Aspira Women'S Health INC | $375.16 | 2022-2024 | Ova1 |
| Bayer Healthcare Pharmaceuticals INC. | $373.28 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $213.96 | 2021-2025 | |
| Organon LLC | $201.89 | 2021-2025 | Nexplanon |
| Biogen, INC. | $195.88 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $163.35 | 2020-2025 | |
| Exeltis, USA INC. | $152.67 | 2019-2025 | Slynd |
| Coopersurgical, INC. | $136.99 | 2019-2024 | Paragard T 380a, Paragard T 380a, Summit Doppler |
| Avion Pharmaceuticals | $131.62 | 2019-2021 | |
| Exact Sciences Corporation | $122.53 | 2023-2025 | Cologuard Collection Kit |
| Intuitive Surgical, INC. | $118.49 | 2022 | |
| Millicent US INC | $118.12 | 2022-2025 | Intrarosa, Femlyv, Femring |
| Merck Sharp & Dohme LLC | $97.82 | 2019-2023 | Gardasil 9 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $93.10 | 2021-2022 | |
| Evofem Biosciences, INC. | $87.71 | 2020-2022 | |
| Mylan Pharmaceuticals INC. | $75.84 | 2019-2022 | |
| Daiichi Sankyo INC. | $75.11 | 2019-2022 | |
| Shield Therapeutics INC | $73.81 | 2023-2025 | Accrufer |
| Sumitomo Pharma America, INC. | $66.66 | 2024-2025 | Myfembree, Gemtesa |
| Channel Medsystems, INC. | $62.40 | 2022 | |
| Therapeuticsmd, INC. | $57.12 | 2020-2022 | |
| Scynexis, INC. | $50.28 | 2022 | |
| Lupin INC. | $49.94 | 2019 | |
| Allergan, INC. | $39.26 | 2019 | |
| Medtronic, INC. | $29.29 | 2022-2023 | Truclear |
| Duchesnay USA Incorporated | $28.83 | 2019 | |
| Pharmacosmos Therapeutics INC. | $19.66 | 2021 | |
| Minerva Surgical, INC | $15.55 | 2025 | |
| Roche Diagnostics Corporation | $15.41 | 2020 | |
| Endo Pharmaceuticals INC. | $14.93 | 2019 | |
| Hologic Sales and Service, LLC | $14.85 | 2024 | Fluent Fluid Management System |
| Amgen INC. | $14.49 | 2019 | |
| Seqirus USA INC | $13.09 | 2020 | |
| Sanofi Pasteur INC. | $12.74 | 2019 | |
| Olympus America INC. | $11.95 | 2022 | |
| Myovant Sciences INC. | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.